Gossamer Bio's (GOSS) "Buy" Rating Reiterated at HC Wainwright

Gossamer Bio (NASDAQ:GOSS - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They presently have a $10.00 price target on the stock.

GOSS has been the subject of a number of other research reports. Oppenheimer started coverage on shares of Gossamer Bio in a research report on Tuesday, June 25th. They set an "outperform" rating and a $9.00 target price for the company. Wedbush reiterated an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group restated a "buy" rating and set a $8.00 target price on shares of Gossamer Bio in a research report on Monday, June 17th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Gossamer Bio has an average rating of "Buy" and an average price target of $9.20.

Gossamer Bio Stock Performance

Shares of GOSS stock traded up $0.02 on Friday, hitting $0.88. 590,666 shares of the stock were exchanged, compared to its average volume of 1,610,847. The firm's 50 day moving average is $0.97 and its two-hundred day moving average is $0.94. Gossamer Bio has a one year low of $0.45 and a one year high of $1.60. The firm has a market capitalization of $198.58 million, a PE ratio of -0.81 and a beta of 1.93. The company has a current ratio of 7.13, a quick ratio of 7.13 and a debt-to-equity ratio of 7.37.

Insider Buying and Selling

In other Gossamer Bio news, CEO Faheem Hasnain acquired 372,000 shares of the company's stock in a transaction that occurred on Friday, June 21st. The stock was bought at an average price of $0.67 per share, with a total value of $249,240.00. Following the completion of the purchase, the chief executive officer now owns 5,408,073 shares of the company's stock, valued at $3,623,408.91. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.00% of the stock is currently owned by insiders.

Institutional Trading of Gossamer Bio

Hedge funds have recently bought and sold shares of the company. Algert Global LLC purchased a new position in shares of Gossamer Bio in the second quarter worth $75,000. The Manufacturers Life Insurance Company grew its holdings in Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company's stock worth $279,000 after acquiring an additional 124,913 shares during the last quarter. NEA Management Company LLC increased its position in shares of Gossamer Bio by 14.2% in the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company's stock valued at $16,300,000 after acquiring an additional 2,255,025 shares during the period. Marshall Wace LLP raised its stake in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company's stock valued at $3,002,000 after acquiring an additional 2,103,766 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Gossamer Bio by 204.7% during the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company's stock worth $1,844,000 after purchasing an additional 1,375,000 shares during the period. Institutional investors own 81.23% of the company's stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.